Psilocybin’s Psychiatric Renaissance: From Ritual to Regulation
A comprehensive review in *Psychiatry and Clinical Neurosciences* charts the remarkable journey of psilocybin, a classic psychedelic, from its historical use in spiritual rituals to its current status as a promising investigational treatment for psychiatric disorders. The article synthesizes evidence from recent clinical trials, which have reported therapeutic effects for major depressive disorder (MDD), depression associated with life-threatening illness, and some substance use disorders. It notes that several phase III trials for depression are now underway, though data for conditions like obsessive-compulsive disorder and bipolar depression remain limited. The review also covers neuroimaging findings, which have primarily focused on MDD, and outlines the evolving, varied international regulatory landscape, where controlled use is now permitted in several countries despite widespread prohibition.
Why it might matter to you: This review provides a critical, evidence-based snapshot of a rapidly advancing frontier in psychopharmacology. For clinicians and researchers in psychiatry, it highlights the specific disorders where psilocybin shows the most promise and pinpoints the significant gaps—such as long-term safety data and standardized protocols—that must be addressed. Understanding this evolving landscape is essential for informed clinical discussions, future trial design, and navigating the complex regulatory shifts that could soon impact treatment availability.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
